Jakafi (ruxolitinib) - Incyte
LAMB1 accelerates esophageal squamous cell carcinoma by triggering JAK2/STAT3 signaling. (PubMed, Mol Biol Rep) - Oct 16, 2026 - "LAMB1 facilitates ESCC malignant progression via activating the JAK2/STAT3 pathway. LAMB1 may serve as a promising prognostic biomarker and therapeutic target for ESCC." 
Journal • Esophageal Squamous Cell Carcinoma • Oncology • Solid Tumor • Squamous Cell Carcinoma • LAMB1
http://www.ncbi.nlm.nih.gov/pubmed/42878970
 
Huilai Lv; Lianmei Zhao; Minghao Zhang; Zhao Liu; Zhenhua Li; Ziqiang Tian
 
Oct 16, 2026
 
Prev Next